Neogen Chemicals Q1 FY27: PAT +67%, OPM at 19%

Key takeaway from the quarter

Neogen Chemicals reported a sharp improvement in Q1 FY27 profitability alongside strong year-on-year revenue growth, supported by better operating margins. Consolidated revenue from operations rose to ₹250.29 crore, while profit after tax (PAT) climbed to ₹17.11 crore. Operating margin expanded to around 19%, the highest level seen in at least eight quarters as per the quarter-wise data shared.

But the results also highlighted constraints that analysts continue to track closely: elevated interest costs, a relatively low return on equity, and weakening capital efficiency metrics. A proprietary “Mojo score” of 64 out of 100 was cited as placing the stock in HOLD territory, reflecting a balanced view despite the strong quarter.

Revenue growth stays strong, sequential growth moderates

For the quarter ended June 30, 2026, Neogen Chemicals posted consolidated revenue from operations of ₹250.29 crore, up 34.04% year-on-year from ₹186.73 crore in Q1 FY26. On a sequential basis, revenue increased 1.51% from ₹246.56 crore in Q4 FY26. The company’s commentary positioned this as the highest quarterly revenue in its recent history, pointing to sustained demand for its specialty chemical portfolio.

Other income was ₹3.86 crore in Q1 FY27, higher than ₹1.18 crore in Q1 FY26 and ₹0.98 crore in Q4 FY26. Total income stood at ₹254.15 crore, a 35.25% year-on-year rise and a 2.67% quarter-on-quarter increase.

Margins improve, helped by mix and efficiencies

The operating story was one of the most notable parts of the quarter. Operating profit (PBDIT excluding other income) rose to ₹48.23 crore, taking the operating margin to 19.27% in the quarter-wise table. Separately, the results note referenced an operating margin of 19.35% for Q1 FY27 versus 17.82% in Q4 FY26.

The operating margin improvement was attributed to a favourable product mix and improved operational efficiencies. Employee costs were a partial offset, rising to ₹25.30 crore from ₹19.57 crore year-on-year.

PAT margin improved to 6.84% in Q1 FY27, up from 4.62% sequentially and 5.49% year-on-year, reflecting operating leverage.

Interest costs remain a drag on net profitability

Despite stronger operating performance, finance costs continued to consume a significant portion of operating profits. Interest cost was ₹20.81 crore in Q1 FY27, marginally lower than ₹21.47 crore in Q4 FY26, but still elevated in the context of quarterly operating profit.

Profit before tax (PBT) rose 62.91% year-on-year to ₹23.28 crore, versus ₹14.29 crore in Q1 FY26. On a quarter-on-quarter basis, PBT increased 46.88% from ₹15.85 crore in Q4 FY26. The share of profit of associates or joint venture contributed ₹0.20 crore in Q1 FY27, compared with ₹0.05 crore in Q1 FY26.

Tax expense was ₹6.17 crore, including current tax of ₹6.03 crore and deferred tax of ₹0.14 crore. The effective tax rate was cited at 26.50%, down from 28.14% in the prior quarter.

Consolidated PAT up 66.76% YoY; EPS rises

Net profit after tax surged 66.76% year-on-year to ₹17.11 crore from ₹10.26 crore in Q1 FY26. Sequentially, PAT increased 50.22% from ₹11.39 crore in Q4 FY26.

Total comprehensive income was ₹17.28 crore, including net other comprehensive income of ₹0.17 crore. Basic and diluted EPS for the quarter was ₹6.29 per share (not annualised), up from ₹3.89 in Q1 FY26 and ₹4.32 in Q4 FY26.

Standalone snapshot and the ₹600 crore QIP plan

In a separate update, Neogen Chemicals’ standalone Q1 net profit was reported at ₹19.4 crore, up about 36.62% year-on-year from ₹14.2 crore. Standalone revenue from operations was cited at ₹252 crore, up 40% year-on-year from ₹180 crore.

Alongside the quarter’s operational performance, the board approved fundraising of up to ₹600 crore through a Qualified Institutional Placement (QIP) route.

Dahej fire insurance recoveries and operating continuity

The company also received a fresh ₹15 crore insurance payment on July 16, 2026, towards the Dahej SEZ plant fire incident, taking total on-account claim recoveries to ₹155 crore.

For FY 2024-25, it recognised a net loss of ₹13.56 crore (₹14.08 crore on a consolidated basis) after accounting for the damage and insurance receivables. The total assessed loss was ₹348.16 crore, against which an insurance claim receivable of ₹334.60 crore was recognised. The company also realised ₹9.38 crore from the sale of salvaged scrap and incurred incidental charges of ₹1.41 crore, which were claimed under the insurance policy.

Production at the affected MPP3 facility remained temporarily suspended, while the replacement plant’s construction was described as progressing rapidly with commissioning scheduled for H1 FY27. The company also indicated shifting production of select specialty products to other sites with customer approval and proceeding with a planned expansion at its Patancheru plant.

Capital efficiency and why analysts remain cautious

Even with improved profitability, the capital efficiency picture remains a key concern. Neogen Chemicals’ average return on equity (ROE) was cited at 6.86%, described as substantially below industry standards. Together with elevated debt and interest costs, this has contributed to a cautious stance by analysts.

A proprietary Mojo score of 64 out of 100 was highlighted as placing the company in HOLD territory, capturing the trade-off between improving margins and lingering balance-sheet constraints.

Market snapshot and upcoming earnings call

On the market day referenced, Neogen Chemicals shares fell 0.26% to close at ₹2,182.60, with 124,804 shares traded.

The company scheduled its Q1 FY27 earnings conference call for Monday, July 27, 2026 at 4:00 PM IST, where management is expected to discuss results and updates on key capex developments.

Key financial snapshot (consolidated)

Recent quarterly trend (as shared)

Why the quarter matters

Neogen’s Q1 FY27 numbers show the company’s ability to lift margins materially while maintaining strong year-on-year growth in revenue. The operating margin moving to about 19% is a key datapoint, particularly after a period of lower margins in prior quarters.

At the same time, the income statement shows how sensitive net profitability remains to finance costs, with interest expenses still high relative to operating profit. That dynamic, combined with low ROE and the backdrop of elevated debt, explains why the quarter has not fully shifted the broader analyst stance.

Conclusion

Neogen Chemicals delivered a strong Q1 FY27 with record consolidated revenue, a sharp rise in PAT, and operating margin at the highest level in recent quarters. The upcoming July 27 earnings call, the planned ₹600 crore QIP, and further updates on the Dahej replacement plant commissioning in H1 FY27 are the next key milestones for investors to track.